Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
How would you approach EGPA with renal involvement that was on maintenance Rituximab, last infusion two months ago and develops new onset liver involvement?
Other causes if liver disease excluded.
Related Questions
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
Do you send anti-human neutrophil elastase antibodies when you suspect levamisole-induced ANCA vasculitis?
How do you approach the workup and management of isolated orbital inflammatory pseudotumor/granuloma?
How would you manage a patient with ANCA associated vasculitis who has recurrent flare including pulmonary hemorrhage, persistent MPO antibody positivity while on maintenance rituximab and avacopan regimen even after induction rituximab therapy?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
What is your approach to patients with GCA who have difficulty with prednisone weaning (20mg) despite use of tocilizumab?
Has anyone successfully gotten insurance approval for avacopan for ANCA-negative GPA?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How do you approach the workup of clinically diagnosed cutaneous vasculitis in healthy young individuals without systemic symptoms?
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?